Foresite Capital Fund IV L.P. 13D and 13G filings for Kinnate Biopharma Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-05-10 5:20 pm Purchase | 2023-05-08 | 13D | Kinnate Biopharma Inc. KNTE | Foresite Capital Fund IV L.P. | 13,718,311 29.500% | 1,780,000 (+14.91%) | Filing |
| 2023-02-22 3:01 pm Purchase | 2023-02-17 | 13D | Kinnate Biopharma Inc. KNTE | Foresite Capital Fund IV L.P. | 11,938,311 25.600% | 1,100,000 (+10.15%) | Filing |
| 2020-12-14 9:24 pm Purchase | 2020-12-03 | 13D | Kinnate Biopharma Inc. KNTE | Foresite Capital Fund IV L.P. | 10,838,311 25.000% | 10,838,311 (New Position) | Filing |